Maxim Group downgraded Sonoma Pharmaceuticals (NASDAQ: SNOA) from Buy to Hold. Analyst Jason Kolbert cited higher share count and risk ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE